Catestatin (Chromogranin A352-372): Novel effects on mobilization of fat from adipose tissue through regulation of adrenergic and leptin signaling

Gautam K. Bandyopadhyay1, 2, Christine U. Vu2, Stefano Gentile2, Howon Lee2, Nilmia Biswas2, Nai-Wen Chi1, 2, Daniel T. O’Connor1, 2 and Sushil K. Mahata1, 2.

1VA San Diego Healthcare System, San Diego, California, USA
2Department of Medicine, University of California, San Diego, California, USA.

Running title: Catestatin and lipid mobilization.

To whom correspondence should be addressed: Sushil K. Mahata, Ph.D., Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0838, Tel (858)-552-8585, ext. 2637; Fax (858)-642-6425; E-mail: smahata@ucsd.edu or Gautam K. Bandyopadhyay, Ph.D. Email: gbandyopadhyay@ucsd.edu

Key words: Catestatin, triglyceride, glycerol, fatty acid, β-oxidation.

Background: Mice lacking the neurosecretory protein Chromogranin A are obese, presumably due to resistance to catecholamines and leptin.

Results: Catestatin (CST) reduces adiposity, an effect likely mediated by restoring leptin sensitivity and modulating adrenergic signaling.

Conclusion: CST promotes lipolysis by blocking α-AR signaling and stimulating fatty acid oxidation.

Significance: We propose CST as a candidate anti-obesity agent.

SUMMARY

Chromogranin A knockout (Chga-KO) mice display increased adiposity despite high levels of circulating catecholamines and leptin. Consistent with diet-induced obese (DIO) mice, desensitization of leptin receptors due to hyperleptinemia is believed to contribute to the obese phenotype of these KO mice. In contrast, obesity in ob/ob mice is caused by leptin deficiency. To characterize the metabolic phenotype, Chga-KO mice were treated with a CHGA-derived peptide CST that is deficient in these mice. CST treatment reduced fat depot size and increased lipolysis and fatty acid oxidation. In liver, CST enhanced oxidation of fatty acids as well as their assimilation into lipids, effects that are attributable to the upregulation of genes promoting fatty acid oxidation (Cpt1α, Ppara, Acox and Ucp2) and incorporation into lipids (Gpat and CD36). CST did not affect basal or isoproterenol-stimulated cAMP production in adipocytes but inhibited phospholipase-C activation by the α-AR agonist phenylephrine, suggesting inhibition of α-AR signaling by CST. Indeed, CST mimicked the lipolytic effect of the α-AR blocker phentolamine on adipocytes. Moreover, CST reversed the hyperleptinemia of Chga-KO mice and improved leptin signaling as determined by phosphorylation of AMPK and Stat3. CST also improved peripheral leptin sensitivity in DIO mice. In ob/ob mice, CST enhanced leptin-induced signaling in adipose tissue. In conclusion, our results implicate CST in a novel pathway that promotes lipolysis and fatty acid oxidation by blocking α-AR signaling as well as by enhancing leptin receptor signaling.

Chromogranin A (CHGA in humans, Chga in mice), a 48-kDa acidic secretory proprotein (1-3), gives rise to several peptides of biological importance, which include the dysglycemic hormone pancreastatin (PST: CHGA250-301) (4,5), the vasodilator vasostatin (CHGA1-76) (6), and the antihypertensive peptide catestatin (CST: CHGA352-372) that inhibits nicotine-induced catecholamine release (7-9). Initially identified as a physiological brake in catecholamine secretion (7), CST has been established as a pleiotropic hormone having effects on promoting angiogenesis (10), lowering of blood pressure (8,11,12) and cardiac contractility (13-15).
as well as enhancing baroreflex sensitivity (16,17) and heart rate variability (18).

In addition to the above cardiovascular functions, CST has an antimicrobial activity (19,20) and also regulates mast cell migration, cytokine production and release (21), smooth muscle cell proliferation (22), and monocyte migration (23). CST can act both extracellularly and intracellularly because the peptide can cross cell membrane (24,25).

Fat cell functions are regulated by catecholamines through four types of adrenergic receptors (AR): \(\beta_1\), \(\beta_2\), \(\beta_3\) and \(\alpha_2\) (26,27). Activation of the three \(\beta\)-ARs is positively coupled to adenylly cyclase by stimulatory GTP sensitive proteins, resulting in enhanced production of cyclic AMP. Cyclic AMP activates protein kinase A (PKA), which in turn phosphorylates hormone sensitive lipase (HSL) leading to hydrolysis of triglycerides (lipolysis). In contrast, \(\alpha_2\)-AR activation has the opposite effects on lipolysis because it is coupled to inhibitory GTP sensitive proteins (28-31). Therefore, the net action of catecholamines depends on the balance between \(\beta\)- and \(\alpha\)-ARs (27). Normally, the \(\beta\)-AR-mediated lipolytic action dominates. Sustained activation of sympathetic nervous system or increased plasma catecholamines is often associated with desensitization of \(\beta\)-AR (32). In vivo studies have shown that the lipolytic action of catecholamines is blunted in obese subjects (33,34). Catecholamine-induced regulation of lipolysis through \(\beta\)-AR desensitization has also been demonstrated in vitro (32,35). Repeated treatment with epinephrine results in the suppression of basal and epinephrine-stimulated lipolysis in lean and obese subjects (36). Even the in vivo lipolytic response to epinephrine is desensitized by prior exposure to epinephrine (37). In view of the above, we hypothesize that the increased fat mass in hyperadrenergic Chga-KO mice (38) reflects \(\beta\)-AR desensitization by increased plasma catecholamines (8). Since catecholamines are known to inhibit leptin secretion (39-41), \(\beta\)-AR desensitization may prevent such inhibition and lead to increased leptin level along with the increased adipose mass as found in Chga-KO mice and other obese models. Chronic hyperleptinemia in turn may desensitize leptin receptor and perpetuate the obese phenotype. Therefore, we reasoned that CST could break this cycle and reduce obesity by restoring AR and leptin receptor sensitivity through normalization of catecholamine and leptin levels. Indeed, we found that chronic CST administration to obese Chga-KO mice resulted in a dramatic lean phenotype. CST treatment also reduced body weight and adipose mass in DIO mice without reducing food intake. Interestingly, CST could enhance leptin effects on adipose tissue metabolism and signaling in both DIO and leptin-deficient \(ob/ob\) mice. Our findings suggest that the reduction in fat mass after chronic CST treatment is due to increased lipolysis and lipid mobilization through CST action on \(\alpha_2\)-AR and leptin receptor. In line with this, CST promoted fatty acid oxidation and leptin signaling.

**EXPERIMENTAL PROCEDURES**

**Animals** - Adult male (7 month old) WT (31.8±1.2 g) and Chga-KO (39.2±1.5 g) mice in the mixed genetic background (129SvJ × C57BL/6) were studied. Both genotypes were generated from the original founder carrying mixed genotype (50% 129SvJ, 50% C57BL/6) and were maintained by sibling mating. Animals were kept in a 12-hr dark/light cycle and fed standard chow ad libitum. Male C57BL/6 mice, 8 week old, were fed a 60% high fat diet (D12492: Research Diets, Inc., New Brunswick) for 16 weeks before using for experiments. Male leptin-deficient (C57BL/6/\(ob/ob\)) mice from the Jackson Laboratory were maintained on a standard chow diet. The Institutional Animal Care and Utilization Committee approved all procedures. Chga-KO, DIO and \(ob/ob\) mice were treated daily with saline or CST (5 µg/g BW, i.p.; 12 days for Chga-KO mice and 16 days for DIO and \(ob/ob\) mice).

**Measurement of glycerol, adipokine, lipid and CST levels in blood and in conditioned media** - Mice were fasted for 12 hr prior to blood draw. Triglycerides (TG) and non-esterified fatty acids (NEFA) were assayed using kits from Wako Diagnostics (Richmond, VA). Glycerol was assayed using a kit from Sigma (St Louis, MO). Media from the explant cultures and mouse serum were assayed. The results were passed through mini C18 columns and the flow-through fractions were assayed. The data were analyzed using a kit from Sigma (St Louis, MO).
same kits were used for measurements in culture media.

Treatment of fat pad explants with CST and leptin – Adipose tissue explants were prepared as described (42). Epididymal fat pads from 12 hr fasted WT, Chga-KO, DIO and ob/ob mice with or without CST treatment were collected in Kreb-Ringer-phosphate (KRP) buffer containing 10 mM Heps and 0.5% BSA. Tissues were minced to 1-2 mm size and treated with 100 nM CST, 1 µM leptin, or saline for 30 min (for signaling analysis) or 3 hr (for lipolysis and β-oxidation assays). Explants were also treated acutely with CST, leptin, a combination, or saline. At the end, incubation media were saved for analysis of glycerol and fatty acids. Explants were washed prior to homogenization for immunoblotting and analysis of fatty acid oxidation.

Preparation of primary adipocytes – Primary adipocytes were isolated from epididymal fat pads essentially as described (43). Adipose tissues from WT and Chga-KO mice were minced in Krebs-Ringer bicitrate-Heps (KRBB) buffer, pH 7.4, containing 10 mM bicarbonate, 30 mM Heps, 200 mM adenosine, 2.5 mM glucose and 1% fatty-acid-free BSA, and digested for 30-40 min with Type I collagenase (10 mg/g tissue; Invitrogen, Carlsbad, CA) with gentle swirling in a 37ºC incubator. The digestion mixture was then filtered through a nylon strainer and centrifuged at 400xg for 1 min. The oily layer (released from broken cells) above floating fat cells was skimmed off, and fat cells were recovered from the top and washed three times with warm KRBB.

Immunoblotting of signaling molecules – Adipose tissue explants after treatments ex vivo and tissues from mice treated in vivo were homogenized in a buffer containing phosphatase and protease inhibitors (20 mM Tris/HCl (pH 7.5), 250 mM sucrose, 2 mM EDTA, 2 mM EGTA, 2 mM Na3VO4, 10 mM NaF, 2 mM Na2P2O7, 1 mM PMSF, 20 µg/ml leupeptin, 10 µg/ml aprotonin, and 1 µM LR-microcystin) as described (38,44). Homogenates were subjected to SDS-PAGE and immunoblotted. Primary antibodies for AMPK and Stat3 were from Cell Signaling Technology (Beverly, MA). The chemiluminescence kit was from Pierce (Rockford, IL).

Incorporation and oxidation of fatty acid in vivo – Mice were injected with saline or CST (5 µg/g BW, i.p.; twice daily) for 12 days. One hr after the final injection, U-14C-palmitate (5 µCi, 100 µl, 0.2 mM) was injected i.p. and mice were sacrificed 3 hr later. Liver and adipose tissues (~100 mg) were homogenized in 0.8 ml 3.5 N perchloric acid and extracted by vortexing in 3 ml of a mixture of methanol and chloroform (2:1, v/v). To the final homogenate, 1.2 ml of 3.5 N perchloric acid was added. The mixture was vortexed and centrifuged. The lower (chloroform) layer contained all the lipids derived from the incorporation of 14C-palmitate, whereas the upper acidic layer contained partially oxidized acid-soluble metabolites (ASM) of 14C-palmitate. The lower layer was further fractionated by thin layer chromatography on silica gel plates using hexane: diethyl ether: acetic acid (79:20:1, v/v/v) mixture as the developing solvent. Lipogenesis from palmitate was determined based on the radioactivity of the free palmitic acid band compared to other lipids (phospholipids, triglycerides, diacylglycerol, etc.) on the TLC plate. Complete oxidation of 14C-palmitate was measured in cultured cells but not in mice.

Fatty acid oxidation in explants and cultured cells. Oxidation of radiolabeled palmitate in the homogenates of adipose tissue explants as described previously (45). For oxidation studies of cultured cells, HepG2 (hepatocytes) and 3T3-L1 preadipocytes were obtained from ATCC and cultured following supplier’s protocol. Confluent 3T3-L1 cultures were differentiated into adipocytes by treating with a cocktail of dexamethasone (100 nM), IBMX (1 µM) and insulin (100 nM) for 10 days. Media were then switched to serum-free DMEM with 1% BSA. Hepatocytes were assayed for lipogenesis and fat oxidation in response to CST treatment. Serum-free cultures were treated with CST (100 nM) for 24 hr followed by a 2 hr incubation with U14C-palmitate (0.5 µCi/ml). Fatty acid oxidation in cells was determined by modifying a published method (46). Specifically, the culture media in 24-well plates were acidified with 10% HClO4 after incubation with the labeled fatty acid and immediately covered with a thick filter paper sheet (cut to size) soaked in 2 N NaOH and placed underneath the plastic lid. The whole plate was sealed with parafilm. After further incubation for 2 hr, the filter paper sheet was marked as circles around the rim of the wells and then the circles were excised. The filter discs were counted to determine the amount of 14CO2 absorbed in the papers. Cells in the culture wells were lysed.
in 1 N NaOH and protein content was assayed using Folin’s reagent (BioRad, Hercules, CA).

Real-Time PCR - RNA was extracted using a kit (RNeasy Plus, Qiagen, Valencia, CA) according to the manufacturer’s specifications. After DNase digestion, 100 ng of RNA was transcribed into cDNA in a 20-µl reaction using a High Capacity cDNA kit (Invitrogen, Carlsbad, CA), analyzed, and amplified. PCR was performed in a 25-µl reaction containing 5 µl of cDNA (one-fifth diluted), 2×SYBR Green PCR Master Mix, and the primers described in Table 1 (400 nM each). Differences in cycle threshold values (ΔCt) between target and the housekeeping gene GAPDH were used to calculate the levels of expression.

Statistics - Data are expressed as the mean ± S.E.M. Curve fitting was accomplished using the program Kaleidagraph (Synergy Software, Reading, PA). Statistical analyses were done by Student’s t-test or one-way ANOVA followed by Bonferroni’s post hoc test. Statistical significance was defined as p < 0.05.

RESULTS

Effects of CST on adiposity, plasma lipid and leptin levels in overweight Chga-KO mice - Plasma CST concentration was 3.8 ng/ml in WT mice fed with a normal chow diet (NCD: Fig. 1A). Administration of CST (5 µg/g BW, i.p./day for 12 days) to these mice raised CST concentration to 7.0 ng/ml (Fig. 1A) and maintained at this level for at least 4 hr (data not shown). High fat diet (HFD, 60% fat, for 16 weeks) decreased CST levels to 5.7 ng/ml which increased to 5.8 ng/ml upon CST administration. CST administration to CST-deficient Chga-KO mice achieved a lower CST level (2.3 ng/ml) than WT mice. Chronic CST administration (5 µg/g BW, i.p./day for 12 days) to Chga-KO mice reduced epididymal fat pad size to WT level (~25% reduction with respect to body weight of Chga-KO mice) without affecting body weight (Fig. 1B&C) or liver weight (Saline: 1.20±0.08 g versus CST: 1.27±0.07 g). Interestingly, CST decreased plasma TG levels in Chga-KO mice (Fig. 1D). This decrease in overall lipid content may be caused in part by increased lipolysis as shown by increased glycerol and NEFA levels in plasma (Fig. 1E&F). We found that Chga-KO mice have higher leptin levels than WT (Fig. 1G), consistent with the established consequence of PST deficiency in the Chga-KO mice (38).

Interestingly, CST treatment of Chga-KO mice lowered plasma leptin to a level below WT (Fig. 1G), suggesting that leptin at subphysiological levels is sufficient to maintain the Chga-KO mice in a lean state. CST also inhibited leptin production in cultured 3T3-L1 adipocytes (Fig. 1H), suggesting a direct effect on leptin secretion independent of other circulating factors. Although leptin is known to facilitate fat oxidation and decrease food intake (47,48), sustained hyperleptinemia may desensitize its receptor and lead to obesity as seen in DIO models (49,50). We therefore reasoned that CST restored leptin action in Chga-KO mice by reversing the desensitization effect of chronic leptin excess. CST did not increase food intake of Chga-KO mice (data not shown), suggesting that CST despite lowering leptin levels preserved leptin signaling in the brain. Leptin-deficient ob/ob mice with sensitive leptin receptors responded to short-term CST treatment by reducing food intake, whereas DIO mice, with peripheral leptin resistance and with a barrier against circulating leptin for hypothalamic action, failed to respond (as discussed later in Fig. 6A&B).

Effects of CST on lipogenesis, fatty acid oxidation and gene expression in Chga-KO mice - In Chga-KO mice treated with CST, we found tissue-specific effects on 14C-palmitate incorporation into lipids. The incorporation was decreased by CST in adipose tissue but enhanced in liver (Fig. 2A&B). In contrast, CST stimulated palmitate oxidation into ASMs in both adipose tissue and liver (Fig. 2C&D). The effect of CST on 14C-palmitate oxidation in cultured hepatocytes (HepG2) and adipocytes (3T3-L1) was measured based on 14CO2 formation (Fig. 2E). Given that adipose tissue in CST-treated mice showed increased palmitate oxidation but decreased incorporation into lipids, we conclude that CST inhibits the expansion of adipose tissue and also promotes fatty acid uptake in liver for oxidation. Liver mRNA analyses revealed that CST augmented the expression of carnitine palmitoyltransferase 1α (Cpt1α), peroxisome proliferator-activated receptor-α (Ppara), acyl-CoA oxidase 1 (Acox1), and uncoupling protein 2 (Ucp2) genes involved in fatty acid oxidation (Fig. 3A-D). In contrast, CST had no effect on the expression of lipogenic genes such as sterol regulatory element-binding protein 1 (Srebp-1) and peroxisome
proliferator-activated receptor-γ (Pparγ) (Fig. 3E). Interestingly, CST stimulated the expression of cluster of differentiation 36 (CD36), a transporter mediating cellular uptake of long-chain fatty acids, as well as the lipogenic gene glycerol-3-phosphate acyltransferase (Gpat4) (Fig. 3E). This indicates that CST stimulates fatty acid incorporation into triglycerides but not de novo lipogenesis. Overall, CST appears to promote lipid flux from adipose tissue toward liver for catabolism.

**Modulation of adrenergic receptor (AR)-mediated lipolysis by CST in adipocytes** - We examined the direct effects of CST in cultured cells. In both 3T3-L1 adipocytes and PC-12 neuroendocrine cells, cAMP production was stimulated by isoproterenol but not by CST (Fig. 4A), indicating that CST did not stimulate β-AR signaling. In contrast, CST attenuated phospholipase C (PLC) activation by both phenylephrine (an α-AR agonist) and epinephrine in 3T3-L1 adipocytes (Fig. 4B). Since epinephrine activates both α- and β-AR, the inhibition of its effect on PLC by CST might represent selective inhibition of α-AR. Of note, CST itself mildly stimulates PLC but inhibits the stimulatory effect of α-AR agonists (Fig. 4B), suggesting that PLC activation by CST itself is α-AR-independent.

As in Chga-KO mice, CST also inhibited leptin release from 3T3-L1 adipocytes (Fig. 1H) and stimulated glycerol release from primary adipocytes (Fig. 4C). Consistent with the literature (30), we found that in adipocytes, the α-AR antagonist phentolamine stimulated lipolysis and potentiated the lipolytic effects of the β-AR agonist isoproterenol (Fig. 4C). In contrast, the α-AR agonist phenylephrine dampened the lipolytic effect of isoproterenol (Fig. 4C). Both the α-antagonist phentolamine and CST potentiated the effects of isoproterenol (Fig. 4C). These findings suggest that CST recapitulates the lipolytic effect of the α-AR antagonist phentolamine. This commonality of CST with phentolamine, coupled with its ability to inhibit phenylephrine action (Fig. 4B), suggests that CST acts by suppressing α-AR signaling.

**CST re-sensitizes Chga-KO mice to leptin** - Leptin signals through AMPK and MAPK pathways and activates the transcription factor Stat3 (51-53). Chronic elevation of plasma leptin level causes desensitization of its receptor, leading to attenuation of Stat3 phosphorylation (49,50). Acute CST treatment of adipose tissue explants from Chga-KO mice stimulated AMPK phosphorylation (Fig. 5A), an effect likely independent of leptin action because similar stimulation was also seen in cultured hepatocytes. Leptin signaling appeared to be subdued in Chga-KO mice as evidenced by the decreased phosphorylation of AMPK and Stat3 compared to WT following acute leptin treatment (Fig. 5B&D). CST treatment restored leptin’s ability to stimulate the phosphorylation of AMPK (Fig. 5C) as well as Stat3 (Fig. 5D), suggesting that CST-induced lowering of plasma leptin in Chga-KO mice might have re-sensitized leptin receptor.

**Modulation of peripheral leptin action by CST in leptin-resistant DIO mice and leptin-deficient ob/ob mice with sensitive leptin receptors** - In contrast to insulin sensitive Chga-KO mice, DIO and ob/ob mice are insulin resistant and obese. However, DIO mice exhibit peripheral leptin resistance (54-56) whereas ob/ob mice maintain functional leptin receptors and full responsiveness to exogenous leptin (57-60). Since our focus in this work has been to study the regulation of lipid metabolism and leptin action by CST in adipose tissue, not in hypothalamus, we examined their effects *ex vivo* in adipose tissue explants. Adipose tissues from these two models of obesity, DIO and ob/ob mice, offer the opportunity to further clarify our observations in Chga-KO mice. When CST was administered to DIO and ob/ob mice for 16 days, food intake in DIO mice did not change but there was a distinct indication that food intake in ob/ob mice started to level off (Fig. 6A&B). Interestingly, decreased food intake by ob/ob mice was not reflected in any decrease in body weight or adipose tissue mass whereas CST treatment for 16 days decreased body weight and adipose mass in DIO mice without a change in food intake (Fig. 6C&D). Similarly, lipolysis as measured by the plasma concentrations of glycerol and NEFA was not affected in ob/ob mice but was increased by CST treatment in DIO mice (Fig. 6E&F). From this experiment it appears that in terms of food intake during the treatment period, CST might have produced a central effect in leptin sensitive ob/ob mice but not in leptin resistant DIO mice. It is likely that a longer treatment with CST will be necessary to manifest CST effect in ob/ob mice and to translate the observed decrease in food intake into changes in body weight, tissue size and overall metabolism. However, increased lipolysis and decreased body weight and adipose tissue mass
indicated a significant peripheral effect in DIO mice. It should be noted that an average of 1.1 g (2%) decrease in body weight was accompanied with about 2 g decrease in adipose tissue mass.

**CST and leptin effects on adipose explants of DIO and ob/ob mice with or without prior CST treatment in vivo** - While leptin-deficient ob/ob mice possess functional leptin receptors and maintain leptin sensitivity (57-60), DIO mice develop peripheral leptin resistance but maintain partial sensitivity to centrally administered leptin (54-56). To examine the direct effects of leptin on adipose tissue lipolysis and fatty acid oxidation, and the influence of CST on leptin action, we treated DIO and ob/ob mice with CST or saline, and exposed adipose explants to leptin for 30 min (for AMPK and Stat3 signaling) or 3 hr (for lipolysis and fatty acid oxidation analysis). After incubation with leptin, an analysis of glycerol and NEFA released into the media demonstrated that while the explants from CST-treated DIO mice (exposed to both CST and leptin in vivo) can release some glycerol in the media, the greatest lipolytic response was produced when leptin was added to the cultures of CST treated explants (Fig. 7A). CST effects on NEFA release by the explants from CST-treated DIO mice was not significant. It is possible that the released NEFA might have undergone further metabolism during the 3 hr incubation. Nevertheless, addition of leptin to the cultures of CST-treated explants resulted in augmented release of NEFA (Fig. 7B). It should be noted that leptin treatment did not stimulate lipolysis of explants from saline-treated mice (Fig. 7A&B). These findings suggest that leptin resistance exists in adipose tissues of DIO mice and that prior CST treatment in vivo might have improved leptin receptor functions. In contrast to DIO mice, 16 days of CST administration alone to ob/ob mice did not influence lipolysis in the explants, whereas the addition of leptin to the cultures of explant from saline-treated ob/ob mice (CST naive) stimulated lipolysis (Fig. 7C&D), suggesting that (i) functional leptin receptors were present in the adipose tissue explants from ob/ob mice, and (ii) CST did not directly influence leptin receptor functions. However, adding leptin to the incubation with CST-treated explants from ob/ob mice produced the highest lipolytic response (Fig. 7C&D). The regulation of palmitate oxidation by the explants in response to CST and leptin followed a pattern similar to lipolysis. Specifically, neither CST nor leptin alone stimulated oxidation in explants from DIO mice but the combination had a stimulatory effect (Fig. 7E), and the treatment with leptin alone (not CST alone) was stimulatory for oxidation in ob/ob explants but the combination showed highest oxidation (Fig. 7F).

Leptin treatment alone did not stimulate Stat3 or AMPK phosphorylation in DIO explants treated with saline (Fig. 8A&B). The treatment of DIO explants with CST in vivo stimulated the phosphorylation of Stat3 but not AMPK. It appears that CST may have a direct, leptin-independent effect on Stat3 phosphorylation. Sequential treatment with CST (in vivo) and leptin (ex vivo) resulted in the highest phosphorylation of both Stat3 and AMPK (Fig. 8A&B). In ob/ob explants, the treatments with leptin alone stimulated phosphorylation of both Stat3 and AMPK (Fig. 8C&D). Again, the treatment with a combination of leptin and CST showed the highest response. The CST stimulation of Stat3 phosphorylation in insulin resistant models (DIO and ob/ob mice, Fig. 8) should be contrasted with the CST effects in insulin sensitive Chga-KO mice (Fig. 5). The lack of CST stimulation of Stat3 phosphorylation in the explants from Chga-KO mice (Fig. 5D) may represent the effects of other missing Chga peptides in the Chga-KO mice that gave rise to the increased insulin sensitivity in those mice. Conversely, CST alone significantly stimulated pAMPK signaling in Chga-KO mice (Fig. 5A). It suggests that other Chga-derived peptides could have a suppressive effect on AMPK signaling stimulated by CST.

**DISCUSSION**

In this study, we found a novel CST function that reduces adiposity and mobilizes lipids from fat depot. These CST effects were examined in Chga-KO mice, where the lack of endogenous CST provided an ideal background for demonstrating the effects of exogenous CST. Another advantage of these mice over WT is their expanded adiposity on a regular chow diet, obviating the need for diet-induced obesity. Moreover, their circulating catecholamine levels are higher than WT (38) and desensitize adipose tissue to catecholamine-induced lipolysis. Likewise, Chga-KO mice also possess higher-than-WT plasma levels of leptin, adiponectin and ketone bodies (38), yet their adiposity was not reduced despite increased lipid oxidation. These observations suggested that Chga-KO mice might
be resistant to hormones such as catecholamines and adipokines, and that alleviation of the resistance could potentially explain the metabolic effect of exogenous CST. In fact, CST treatment in Chga-KO mice not only lowered high levels of circulating catecholamines and leptin (38) but also reduced adipose tissue size by ~25% (Fig. 1C).

It appears that CST promotes lipolysis in adipose tissue (Fig. 1E) as well as fatty acid uptake and oxidation in liver (Fig. 2). In other words, CST treatment created an environment where lipolytic products (glycerol and fatty acids) were not re-esterified for storage. Therefore, its net metabolic effect is to favor lipid disposal. Of note, the lipid disposal promoted by CST was not mediated by increased catecholamine or leptin release. On the contrary, CST inhibits catecholamine release and oxidation in liver (Fig. 2). In other words, CST treatment created an environment where lipolytic products (glycerol and fatty acids) were not re-esterified for storage. Therefore, its net metabolic effect is to favor lipid disposal. Of note, the lipid disposal promoted by CST was not mediated by increased catecholamine or leptin release. On the contrary, CST inhibits catecholamine release (7,61,62) and leptin production (Fig. 1G).

Since CST did not modulate basal or isoproterenol-induced cAMP levels in PC-12 cells (Fig. 4A), its lipolytic effect is probably not mediated by β-AR signaling. Instead, inhibition of α-AR signaling may underlie the lipolytic effect of CST given its ability to prevent phenylephrine from activating PLC. Existing literature indicates that α-AR signaling inhibits lipolysis whereas α-AR blockade potentiates the lipolytic effect of β-AR signaling (29,30,63,64). Acting like an α-AR antagonist, CST enhanced the lipolytic effect of β-AR agonists (Fig. 4C). Under physiological conditions, α-AR dominates over β-AR, leading to overall lipogenesis (28). Therefore, α-AR inhibition by CST might have shifted the balance towards lipolysis.

In obese states, increased circulating levels of leptin cause desensitization of its receptors, resulting in failure of leptin to reduce food intake and promote lipid oxidation (49,50). In this context, the ability of CST to decrease leptin production and minimize chronic overexposure might have restored leptin sensitivity in brain and peripheral tissues. Therefore, the net result was increased oxidation of lipolytic product (NEFA). Leptin signaling through AMPK and Stat3 in Chga-KO mice following acute leptin treatment was subdued compared to WT. CST treatment restored leptin action in Chga-KO mice, suggesting re-sensitization of the leptin receptor.

To further clarify the interactions between CST and leptin pathways and to establish CST as an anti-obesity factor, we examined the effects of CST in leptin resistant DIO mice and leptin deficient ob/ob mice. DIO mice are known to exhibit peripheral leptin resistance (54-56). We observed leptin resistance in adipose tissue explants from DIO mice whereas CST treatment alone did not stimulate lipolysis, β-oxidation, or phosphorylation of Stat3 and AMPK. However, prior CST treatment of DIO mice for 16 days led to the sensitization of all acute leptin effects in the adipose tissue explants, suggesting sensitization of leptin receptor-like functions in adipose tissue. CST administration to DIO mice did not reduce food intake but actually caused a modest reduction in body weight proportional to the loss of adipose mass. As a result, the products of lipolysis, glycerol and NEFA, were increased in serum.

Unlike DIO mice, leptin-deficient ob/ob mice maintain leptin sensitivity (57-60). As a result, acute treatment of adipose explants with leptin stimulated lipolysis, fatty acid oxidation, and phosphorylation of Stat3 and AMPK. The leptin effects were enhanced in the explants from CST treated ob/ob mice whereas CST treatment alone did not show significant peripheral effects. It should be noted that the treatment of ob/ob mice with CST for 16 days started to reduce food intake (by 25%) resembling a leptin-like effect. This is in contrast to DIO mice, where CST treatment did not reduce food intake. One of the reasons for the failure of leptin to reduce food intake by activating hypothalamic leptin receptors in DIO mice is limited delivery of circulating leptin across the blood brain barrier. When administered through the intracerebroventricular (i.c.v.) route, leptin could activate hypothalamic receptor signaling in DIO mice is limited delivery of circulating leptin across the blood brain barrier. When administered through the intracerebroventricular (i.c.v.) route, leptin could activate hypothalamic receptor signaling in DIO mice (54-56). It is therefore highly possible that like leptin, i.c.v. administration of CST might reduce food intake in DIO mice and enhance hypothalamic leptin response. Administration of CST to DIO mice by the i.p. route, on the other hand, could generate only peripheral response and improve peripheral leptin sensitivity. It is also possible that CST acted centrally in ob/ob mice to reduce food intake but longer treatment is required (6-8 weeks instead of 16 days) to initiate a reduction of body weight and adipose tissue mass. We will address these possibilities in a future work. Restoration of leptin-mediated AMPK signaling and fatty acid oxidation in DIO mice by CST with concomitant reduction in body weight and fat mass suggests a crucial
physiological role of CST in fine-tuning lipid metabolism to prevent obesity. We have also seen that CST stimulates lipolysis by antagonizing α-AR functions. Is there an inverse relationship between α-AR and leptin receptor functions where CST could be a key regulator? We will explore these possibilities in future.

In conclusion, our data support an essential role of the endogenous bioactive peptide CST in restoring homeostasis during metabolic disorders by controlling catecholamine release and lipid disposal via modulation of adrenergic and leptin signaling.

Acknowledgments - This work was supported by grants from the Department of Veterans Affairs (SKM, DTOC, NWC) and the National Institutes of Health (R01 DA011311 to SKM).

REFERENCES

1. Winkler, H., and Fischer-Colbrie, R. (1992) Neuroscience 49, 497-528
2. Taupenot, L., Harper, K. L., and O’Connor, D. T. (2003) New Engl J Med 348, 1134-1149
3. Montero-Hadjadje, M., Vaingankar, S., Elias, S., Tostivint, H., Mahata, S. K., and Anouar, Y. (2008) Acta Physiol (Oxf) 192, 309-324
4. Tatemoto, K., Efendic, S., Mutt, V., Makk, G., Feistner, G. J., and Barchas, J. D. (1986) Nature 324, 476-478
23. Egger, M., Beer, A. G., Theurl, M., Schgoer, W., Hotter, B., Tatarczyk, T., Vasiljevic, D., Frauscher, S., Marksteiner, J., Patsch, J. R., Schratzberger, P., Djanani, A. M., Mahata, S. K., and Kirchmair, R. (2008) *Eur J Pharmacol* 598, 104-111
24. Sugawara, M., Resende, J. M., Moraes, C. M., Marquette, A., Chich, J. F., Metz-Boutigue, M. H., and Bechinger, B. (2010) *FASEB J* 24, 1737-1746
25. Helle, K. B. (2010) *Cardiovasc Res* 85, 9-16
26. Arner, P. (1999) *Int J Obes Relat Metab Disord* 23 Suppl 1, 10-13
27. Arner, P. (2005) *Best Pract Res Clin Endocrinol Metab* 19, 471-482
28. Lafontan, M., Barbe, P., Galitzky, J., Tavernier, G., Langin, D., Carpene, C., Bousquet-Melou, A., and Berlan, M. (1997) *Hum Reprod Suppl 1*, 6-20
29. Stich, V., de Glisezinski, I., Crampe, F., Suljkovicova, H., Galitzky, J., Riviere, D., Hejnova, J., Lafontan, M., and Berlan, M. (1999) *Am J Physiol* 277, R1076-1083
30. Stich, V., Pelikanova, T., Wohl, P., Sengenes, C., Zakaroff-Girard, A., Lafontan, M., and Berlan, M. (2003) *Am J Physiol Endocrinol Metab* 285, E599-607
31. Lafontan, M., and Langin, D. (2009) *Prog Lipid Res* 48, 1737-1746
32. Mori, S., Nojiri, H., Yoshizuka, N., and Takema, Y. (2007) *Lipids* 42, 307-314
33. Jensen, M. D. (1997) *Annu Rev Nutr* 17, 127-139
34. Bougneres, P., Stunff, C. L., Pecqueur, C., Pinglier, E., Adnot, P., and Ricquier, D. (1997) *J Clin Invest* 99, 2568-2573
35. Bandyopadhyay, G. K., Yu, J. G., Ofrecio, J., and Olefsky, J. M. (2005) *Diabetes* 54, 2351-2359
36. Wang, M. Y., Orci, L., Ravazzola, M., and Unger, R. H. (2005) *Proc Natl Acad Sci USA* 102, 18011-18016
37. Knight, Z. A., Hannan, K. S., Greenberg, M. L., and Friedman, J. M. (2010) *PLoS One* 5, e11376
38. Kim, Y. B., Uotani, S., Pierroz, D. D., Flier, J. S., and Kahn, B. B. (2000) *Endocrinology* 141, 2328-2339
39. Morris, D. L., and Rui, L. (2009) *J Clin Invest* 105, 1827-1832
55. Lin, S., Thomas, T. C., Storlien, L. H., and Huang, X. F. (2000) *Int J Obes Relat Metab Disord* **24**, 639-646
56. Van Heek, M., Compton, D. S., France, C. F., Tedesco, R. P., Fawzi, A. B., Graziano, M. P., Sybertz, E. J., Strader, C. D., and Davis, H. R., Jr. (1997) *J Clin Invest* **99**, 385-390
57. Pelleymounter, M. A., Cullen, M. J., Baker, M. B., Hecht, R., Winters, D., Boone, T., and Collins, F. (1995) *Science* **269**, 540-543
58. Koch, C., Augustine, R. A., Steger, J., Ganjam, G. K., Benzler, J., Pracht, C., Lowe, C., Schwartz, M. W., Shepherd, P. R., Anderson, G. M., Grattan, D. R., and Tups, A. (2010) *J Neurosci* **30**, 16180-16187
59. Fruhbeck, G., Aguado, M., and Martinez, J. A. (1997) *Biochem Biophys Res Commun* **240**, 590-594
60. Fruhbeck, G., Aguado, M., Gomez-Ambrosi, J., and Martínez, J. A. (1998) *Biochem Biophys Res Commun* **250**, 99-102
61. Mahata, S. K., Mahata, M., Wakade, A. R., and O'Connor, D. T. (2000) *Mol Endocrinol* **14**, 1525-1535
62. Mahata, S. K., Mahata, M., Wen, G., Wong, W. B., Mahapatra, N. R., Hamilton, B. A., and O'Connor, D. T. (2004) *Mol Pharmacol* **66**, 1180-1191
63. Gomez-Ambrosi, J., Fruhbeck, G., Aguado, M., Milagro, F. I., Margareto, J., and Martinez, A. J. (2001) *Int J Mol Med* **8**, 103-109
64. Polak, J., Moro, C., Bessiere, D., Hejnova, J., Marques, M. A., Bajzova, M., Lafontan, M., Crampes, F., Berlan, M., and Stich, V. (2007) *J Lipid Res* **48**, 2236-2246
| Gene   | Forward                         | Reverse                         |
|--------|---------------------------------|---------------------------------|
| Acox1  | GTC GAC CTT GTT CGC CA          | GGT TCC TCA GCA CGG CTT        |
| CD36   | TCC AGC CAA TGC CTT TGC        | TGG AGA ATT ACT TTT TCA GTG CAG AA |
| Cpt1α  | CAG GAT TTT GCT GTC AAC CTC    | GAG CAT CTC CAT GGC GTA G       |
| Gapdh  | TAT GTC GTG GAG TCT ACT GGT GT | GTC ATC ATA CTT GGC AGG TTT CT  |
| Gpat4  | TGT CTG GTT TGA GCG TTC TG     | TTC TGG GAA GAT GAG GAT GG     |
| Ppara  | GGG CTC TCC CAC ATC CTT        | CCC ATT TCG GTA GCA GGT AGT C   |
| Pparγ1 | GAG TGT GAC GAC AAG ATT TG     | GGT GGG CCA GAA TGG CAT CT      |
| Srebp-1c | GGA GCC ATG GAT TGC ACA TT   | GCT TCC AGA GAG GAG GCC AG     |
| Ucp2   | CAG CCA GCG CCC AGT ACC       | CAA TGC GGA CGG AGG CAA AGC    |
FIGURE LEGENDS

FIGURE 1. Plasma parameters of wild-type (WT) and Chga-KO mice treated with saline or CST. (A) Plasma CST from saline or CST (5 µg/g BW, i.p./day) treated WT mice (28 week old) on normal chow (NCD) and high fat diet (HFD: 60% fat for 16 weeks) as well as from Chga-KO mice (28 week old) on NCD. Body weights (B) and epididymal fat pad size normalized to body weight (C) in 28 week old WT and Chga-KO mice treated with saline or CST for 12 days. Plasma triglyceride (TG) (D), glycerol (E), non-esterified fatty acids (NEFA) (F), and leptin (G) in 28 week old WT and Chga-KO mice after treatment with saline or CST for 12 days. (H) Leptin in adipocyte culture media after treatment with saline or CST.

FIGURE 2. Effects of CST on lipogenesis from fatty acid and fatty acid oxidation in hepatic and adipose tissues. Incorporation of 14C-palmitate into lipids in adipose (A) and liver (B) in Chga-KO mice after saline or CST treatment (5 µg/g BW, i.p./day) for 12 days. Partial oxidation to acid soluble metabolites (ASM) in adipose tissue (C) and liver (D). Complete oxidation to 14CO2 in hepatocytes (HepG2) and adipocytes (3T3-L1) after saline or CST treatment (E).

FIGURE 3. Effects of CST on hepatic expression of genes involved in lipogenesis and fatty acid oxidation. Relative mRNA expression of genes involved in fatty acid oxidation in liver of WT and Chga-KO mice after treatment with saline or CST (5 µg/g BW, i.p./day) for 12 days: carnitine palmitoyltransferase 1α (Cpt1α) (A), peroxisome proliferator-activated receptor-α (Pparα) (B), acyl-CoA oxidase 1 (Acox1) (C) and uncoupling protein 2 (Ucp2) (D). (E) Relative expression of genes involved in lipogenesis in liver of Chga-KO mice after treatment with saline or CST (5 µg/g BW, i.p./day) for 12 days: sterol regulatory element-binding protein 1 (Srebp-1), peroxisome proliferator-activated receptor-γ (Pparγ), glycerol-3-phosphate acyltransferase (Gpat4) and cluster of differentiation 36 (Cd36).

FIGURE 4. Regulation of adrenergic signaling by CST as measured by cAMP production, phospholipase C activity, and lipolytic glycerol release. (A) Effects of CST (100 nM, 10 min) on cAMP production in PC-12 and 3T3-L1 cells pretreated with saline or isoproterenol (ISO) (10 µM) for 10 min. (B) Effects of CST on phospholipase C activity in 3T3-L1 adipocytes pretreated with phenylephrine or epinephrine (10 µM for 10 min). (C) Effects of CST on glycerol release from adipocytes pretreated with ISO, phenylephrine (PEP), and phentolamine (PTA) (10 µM for 10 min).

FIGURE 5. Regulation of AMPK and Stat3 signaling by CST in adipose tissue explants. Explants from Chga-KO mice were treated with saline or CST (100 nM for 30 min) and immunoblotted for pAMPK and AMPK (A). Adipose explants from WT and Chga-KO mice were immunoblotted for pAMPK and AMPK after treatment with saline or leptin (1 µM) for 30 min (B). pAMPK and AMPK (C) and pStat3 and Stat3 (D) signaling in adipose explants from WT and Chga-KO mice after treatment for 30 min with saline, CST (100 nM), leptin (1 µM) or leptin plus CST.

FIGURE 6. Effects of CST administration to DIO and ob/ob mice on food intake, body weight, adipose tissue weight, and lipolysis. CST (5 µg/g BW, i.p./day) or saline was administered to DIO and ob/ob mice for 16 days. Food intake for DIO mice (A) and ob/ob mice (B) was measured every other day. Percent changes in final body weight and white adipose tissue (WAT) mass (as % of body weight) were determined for DIO (C) and ob/ob (D) mice. Plasma glycerol (E) and NEFA (F) were quantified for DIO and ob/ob mice at the end of CST treatment.

FIGURE 7. Lipolysis and fatty acid oxidation in the adipose tissue explants of DIO and ob/ob mice after treatment with saline or CST for 16 days. Explants were incubated with saline or leptin (1 µM) for 3 hr and the concentrations of glycerol (A&C) and NEFA (B&D) released into the media from DIO (A&B) and ob/ob
(C&D) explants were determined as a measure of lipolysis. Homogenates of the explants from DIO (E) and ob/ob (D) were used to determine their capacity for oxidation of U-14C-palmitate in response to the treatment with saline, CST, leptin and CST+leptin. The $^{14}$CO$_2$ released was captured and counted as the measure of fatty acid oxidation.

**FIGURE 8. Stat3 and AMPK signaling in the adipose tissue explants from DIO and ob/ob mice treated with saline, CST (in vivo) and leptin (ex vivo).** Explants from DIO mice (A&B) and ob/ob mice (C&D) were incubated with saline or leptin (1 µM) for 30 min, homogenized and immunoblotted for phospho- and total Stat3 (A&C) as well as phospho- and total AMPK signals (B&D). Results are presented as the ratio of signal strength of phospho- over total.
A. WT NCD  
   WT HFD  
   KO NCD  

Plasma CST (ng/ml)  

Saline (Sal)  
CST  

Body weight (g)  

WT + Sal  
KO + Sal  
KO + CST  

Epididymal fat (% of body weight)  

WT + Sal  
KO + Sal  
KO + CST  

Chga-KO mice  

B.  

C.  

D.  

E.  

F.  

G.  

H.  

3T3-L1 cells  

Leptin (µg/mg protein)  

Plasma Leptin (ng/ml)  

Plasma glycerol (µg/ml)  

Plasma NEFA (nmol/ml)  

Leptin (µg/mg protein)  

WT + Sal  
KO + Sal  
KO + CST  

WT NCD  
KO NCD  

Chga-KO mice  

p<0.006  
p<0.003  
p=0.07  

p<0.001  
p=0.59  

p<0.006  
p<0.0004  

p<0.03  

p<0.0002  
p<0.0003  

p<0.0007  
p<0.0002  

p<0.007  
p<0.0002  

n=4 (all)  
n=4  
n=4  
n=7  
n=7  
n=7  
n=6  
n=7
A. **Adipose: Chga-KO mice**

\[ \text{Saline CST} \]

\[ 14 \text{C-palmitate (x1000 cpm/mg tissue)} \]

\[ p<0.0001 \]

\[ n=6 \]

B. **Liver: Chga-KO mice**

\[ \text{Saline CST} \]

\[ 14 \text{C-Palmitate (x1000 cpm/mg tissue)} \]

\[ p<0.002 \]

\[ n=6 \]

C. **Adipose: Chga-KO mice**

\[ \text{Saline CST} \]

\[ \text{Acid soluble metabolites (x1000 cpm/gm tissue)} \]

\[ p<0.0001 \]

\[ n=6 \]

D. **Liver: Chga-KO mice**

\[ \text{Saline CST} \]

\[ \text{Acid soluble metabolites (x1000 cpm/gm tissue)} \]

\[ p<0.0001 \]

\[ n=6 \]

E. **Cell lines**

\[ \text{Saline CST} \]

\[ 14 \text{CO}_2 \text{ produced (x100 cpm/mg protein)} \]

\[ p<0.001 \]

\[ n=6 \text{ (all)} \]

Bandyopadhyay_Fig. 2
**A.**

**Cpt1α**

Relative mRNA level (normalized to GAPDH)

- WT + Sal
- KO + Sal
- KO + CST

n=8

p<0.001

p<0.0001

**B.**

**Ppara**

Relative mRNA level (normalized to GAPDH)

- WT + Sal
- KO + Sal
- KO + CST

n=6

n=8

p<0.01

p<0.03

**C.**

**Acox1**

Relative mRNA level (normalized to GAPDH)

- WT + Sal
- KO + Sal
- KO + CST

n=6

n=8

p<0.0001

p=0.08

**D.**

**Ucp2**

Relative mRNA level (normalized to GAPDH)

- KO + Sal
- KO + CST

n=6

p<0.0002

**E.**

**Srebp-1**

Relative mRNA level (normalized to GAPDH)

- Saline (n=6)
- CST (n=6)

p<0.0004

p<0.0003

Bandyopadhyay_Fig. 3
A. PC12 3T3-L1

Saline | CST | ISO | ISO+CST

n=6

p<0.0001

p=0.02

p=0.33

p=0.59

p=0.2

p<0.02

p<0.0001

B. 3T3-L1 adipocytes

PLC activity (Units/mg protein)

n=6 (all)

p<0.0003

p<0.005

p<0.006

Sal: + - - - - - -

CST: - + - + - - -

PEP: - - + + - + -

EPI: - - - - + + -

C. Primary adipocytes

Glycerol (µg/ml)

Sal: + - - - - - -

CST: - + - + - - -

ISO: - - + + - + -

PEP: - - - + + - -

PTA: + - - - - + +

p<0.0002

p<0.0001

p<0.0007

p<0.0002

p<0.0001
A. Saline CST

\[
\text{Phospho/Total AMPK (A.U.)} \quad n=4
\]

B. Sal Lep Lep Sal Lep Lep

\[
\text{Phospho/Total AMPK (A.U.)} \quad n=4
\]

C. WT Chga-KO

\[
\text{Phospho/Total AMPK (A.U.)} \quad n=4 \text{ (all)}
\]

D. WT Chga-KO

\[
\text{Phospho/Total Stat3 (A.U.)} \quad n=4 \text{ (all)}
\]
A. **DIO mice**

Food intake (g) per day

![Graph showing food intake for DIO mice with Saline and CST conditions](image)

B. **ob/ob mice**

Food intake (g) per day

![Graph showing food intake for ob/ob mice with Saline and CST conditions](image)

C. **DIO mice**

Percent change

![Bar graph showing percent change in BW and WAT for DIO mice with Saline and CST conditions](image)

D. **ob/ob mice**

Percent change

![Bar graph showing percent change in BW and WAT for ob/ob mice with Saline and CST conditions](image)

E. **Plasma glycerol**

Plasma glycerol (µg/ml)

![Bar graph showing plasma glycerol levels for DIO and ob/ob mice with Saline and CST (5 µg/g) conditions](image)

F. **Plasma NEFA**

Plasma NEFA (mM)

![Bar graph showing plasma NEFA levels for DIO and ob/ob mice with Saline and CST conditions](image)

Bandyopadhyay_Fig. 6
A. **DIO mice**

- Glycerol (µmol/mg protein)
- CST:
- Leptin:
  - n=6 (all)
  - p<0.001
  - p<0.001
  - p<0.05

B. **DIO mice**

- NEFA (µmol/mg protein)
- CST:
- Leptin:
  - n=6 (all)
  - p<0.001

C. **ob/ob mice**

- Glycerol (µmol/mg protein)
- CST:
- Leptin:
  - n=6 (all)
  - p<0.001

D. **ob/ob mice**

- NEFA (µmol/mg protein)
- CST:
- Leptin:
  - n=6 (all)
  - p<0.01

E. **DIO mice**

- \(^{14}\)CO\(_2\) produced (x1000 cpm/mg protein)
- CST:
- Leptin:
  - n=6 (all)
  - p<0.001

F. **ob/ob mice**

- \(^{14}\)CO\(_2\) produced (x1000 cpm/mg protein)
- CST:
- Leptin:
  - n=6 (all)
  - p<0.001
A. **DIO mice**

| CST | Leptin | pStat3 | Stat3 |
|-----|--------|--------|-------|
| -   | -      | ![Phospho/Total Stat3 (A.U.)](image) | ![Phospho/Total Stat3 (A.U.)](image) |
| +   | -      | ![Phospho/Total Stat3 (A.U.)](image) | ![Phospho/Total Stat3 (A.U.)](image) |
| -   | +      | ![Phospho/Total Stat3 (A.U.)](image) | ![Phospho/Total Stat3 (A.U.)](image) |
| +   | +      | ![Phospho/Total Stat3 (A.U.)](image) | ![Phospho/Total Stat3 (A.U.)](image) |

n=4

B. **DIO mice**

| CST | Leptin | pAMPK | AMPK |
|-----|--------|-------|------|
| -   | -      | ![Phospho/Total AMPK (A.U.)](image) | ![Phospho/Total AMPK (A.U.)](image) |
| +   | -      | ![Phospho/Total AMPK (A.U.)](image) | ![Phospho/Total AMPK (A.U.)](image) |
| -   | +      | ![Phospho/Total AMPK (A.U.)](image) | ![Phospho/Total AMPK (A.U.)](image) |
| +   | +      | ![Phospho/Total AMPK (A.U.)](image) | ![Phospho/Total AMPK (A.U.)](image) |

n=4 (all)

C. **ob/ob mice**

| CST | Leptin | pStat3 | Stat3 |
|-----|--------|--------|-------|
| -   | -      | ![Phospho/Total Stat3 (A.U.)](image) | ![Phospho/Total Stat3 (A.U.)](image) |
| +   | -      | ![Phospho/Total Stat3 (A.U.)](image) | ![Phospho/Total Stat3 (A.U.)](image) |
| -   | +      | ![Phospho/Total Stat3 (A.U.)](image) | ![Phospho/Total Stat3 (A.U.)](image) |
| +   | +      | ![Phospho/Total Stat3 (A.U.)](image) | ![Phospho/Total Stat3 (A.U.)](image) |

n=6 (all)

D. **ob/ob mice**

| CST | Leptin | pAMPK | AMPK |
|-----|--------|-------|------|
| -   | -      | ![Phospho/Total AMPK (A.U.)](image) | ![Phospho/Total AMPK (A.U.)](image) |
| +   | -      | ![Phospho/Total AMPK (A.U.)](image) | ![Phospho/Total AMPK (A.U.)](image) |
| -   | +      | ![Phospho/Total AMPK (A.U.)](image) | ![Phospho/Total AMPK (A.U.)](image) |
| +   | +      | ![Phospho/Total AMPK (A.U.)](image) | ![Phospho/Total AMPK (A.U.)](image) |

n=6 (all)

Bandyopadhyay_Fig. 8
Catestatin (Chromogranin A352-372): Novel effects on mobilization of fat from adipose tissue through regulation of adrenergic and leptin signaling
Gautam K. Bandyopadhyay, Christine U. Vu, Stefano Gentile, Howon Lee, Nilima Biswas, Nai-Wen Chi, Daniel T. O'Connor and Sushil K. Mahata

J. Biol. Chem. published online April 25, 2012

Access the most updated version of this article at doi: 10.1074/jbc.M111.335877

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts